The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
Abstract
Purpose: This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer. Patients and Methods: Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m 2 via 24-hour infusion, leucovorin 200 mg/m 2, and oxaliplatin 85 mg/m 2 (FLO) every 2 weeks or fluorouracil 2,000 mg/m 2 via 24-hour infusion, leucovorin 200 mg/m 2 weekly, and cisplatin 50 mg/m 2 every 2 weeks (FLP). The primary end point was progression-free survival (PFS). Results: Two hundred twenty patients (median age, 64 years; metastatic, 94%) were randomly assigned. FLO was associated with significantly less (any grade) anemia (54% v 72%), nausea (53% v 70%), vomiting (31% v 52%), alopecia (22% v 39%), fatigue (19% v 34%), renal toxicity (11% v 34%), thromboembolic events (0.9% v 7.8%), and serious adverse events related to the treatment (9% v 19%). FLP was associated with significantly less peripheral neuropathy (22% v 63%). There was a trend toward improved median PFS with FLO versus FLP (5.8 v 3.9 months, respectively; P = .077) and no significant difference in median overall survival (10.7 v 8.8 months, respectively). However, in patients older than 65 years (n = 94), treatment with FLO resulted in significantly superior response rates (41.3% v 16.7%; P = .012), time to treatment failure (5.4 v 2.3 months; P < .001), and PFS (6.0 v 3.1 month; P = .029) and an improved OS (13.9 v 7.2 months) as compared with FLP, respectively. Conclusion: FLO reduced toxicity as compared with FLP. In older adult patients, FLO also seemed to be associated with improved efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Glimelius, B., Ekström, K., Hoffman, K., Graf, W., Sjödén, P.-O., Haglund, U., Svensson, C., Enander, L.-K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 849
Vanhoefer, U., Rougier, P., Wilke, H., Ducreux, M. P., Lacave, A. J., Van Cutsem, E., Planker, M., Santos, J. G. D., Piedbois, P., Paillot, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2648 · Cited by 531
Goldberg, R. M., Tabah-Fisch, I., Bleiberg, H., de Gramont, A., Tournigand, C., Andre, T., Rothenberg, M. L., Green, E., & Sargent, D. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9039 · Cited by 469
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Caussanel, J.-P., Lévi, F., Brienza, S., Misset, J.-L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B., & Mathé, G. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.12.1046 · Cited by 253
De Vita, F., Orditura, M., Matano, E., Bianco, R., Carlomagno, C., Infusino, S., Damiano, V, Simeone, E., Diadema, M. R., Lieto, E., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602573 · Cited by 179
Carpenter, J. T., Roche, H. H., Campone, M., Colomer, R., Jagiełło-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J. P., & Baselga, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.564 · Cited by 99
Dank, M., Załuski, J., Barone, C., Valvere, V., Peschel, C., Wenczl, M., Göker, E., Risse, M., Awad, L., & Bugat, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4003 · Cited by 87
Lutz, M. P., Wilke, H., Wagener, D. J. T., Vanhoefer, U. J., Jeziorski, K., Hegewisch‐Becker, S., Balleisen, L., Joosens, E., Jansen, R. L., Debois, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1666 · Cited by 69
Self-citation
Cited by
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00797-2 · Cited by 3,041
Sun, J.-M., Shen, L., Shah, M. A., Enzinger, P., Adenis, A., Doi, T., Kojima, T., Metges, J.-P., Li, Z., Kim, S.-B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01234-4 · Cited by 1,635
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Metadata
- Authors
- Al-Batran, S.-E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt, G., Homann, N., Wilhelm, G., Schuch, G., Stoehlmacher, J., Derigs, H. G., Hegewisch-Becker, S., Grossmann, J., Pauligk, C., Atmaca, A., Bokemeyer, C., Knuth, A., & Jäger, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-03-20
- Volume
- 26
- Issue
- 9
- Pages
- 1435-1442
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108661938
- Cited by
- 782
- References
- 11
- FWCI
- 37.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. https://app.cochat.ai/papers/10.1200/jco.2007.13.9378
- The paper
- Al-Batran, S.-E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt, G., Homann, N., Wilhelm, G., Schuch, G., Stoehlmacher, J., Derigs, H. G., Hegewisch-Becker, S., Grossmann, J., Pauligk, C., Atmaca, A., Bokemeyer, C., Knuth, A., & Jäger, E. (2008). Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.13.9378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
